ArticleCancer letters2016
Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancer.
Article in Cancer letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- Clinicopathological and prognostic significance of mucin signatures in lower gastrointestinal cancer-a systematic review and meta-analysis.British journal of cancer · 2026Pooled it
- Histone-lysine N-methyltransferase SETD7 is a potential serum biomarker for colorectal cancer patients.EBioMedicine · 2018Trial
- Diagnostic Significance of Ki-67, p53, and Mucin Glycoprotein Expression in Colorectal Serrated Lesions: Further Immunohistochemical Studies.Diagnostics (Basel, Switzerland) · 2026Article
- Metastatic adenocarcinomas of left colon and rectum: differences in clinical outcome and gene expression.Frontiers in oncology · 2026Article
- Unveiling the protein landscape for early detection of colorectal precancerous lesions.Clinical proteomics · 2025Article
- Associations of mucinous differentiation and mucin expression with immune cell infiltration and prognosis in colorectal adenocarcinoma.British journal of cancer · 2025Article
- Analysis of extracellular vesicles of frequently used colorectal cancer cell lines.BMC cancer · 2025Article
- Exploring the Link Between Mucin 2 and Weaning Stress-Related Diarrhoea in Piglets.International journal of molecular sciences · 2025Article
- Mucins as Precision Biomarkers in Glioma: Emerging Evidence for Their Potential in Biospecimen Analysis and Outcome Prediction.Biomedicines · 2024Review
- Preventative Cancer Vaccine-Elicited Human Anti-MUC1 Antibodies Have Multiple Effector Functions.Antibodies (Basel, Switzerland) · 2024Article
- Colorectal cancer murine models: Initiation to metastasis.Cancer letters · 2024Review
- Increased circulating regulatory T cells and decreased follicular T helper cells are associated with colorectal carcinogenesis.Frontiers in immunology · 2024Article
- Expression of anoctamin 7 (ANO7) is associated with poor prognosis and mucin 2 (MUC2) in colon adenocarcinoma: a study based on TCGA data.Genomics & informatics · 2023Article
- Invasive stratified mucin-producing carcinoma of the colorectum: expanding the morphologic spectrum of large bowel cancer.Diagnostic pathology · 2023Article
- Analysis of MUC6 polymorphisms on the clinicopathologic characteristics of Asian patients with oral squamous cell carcinoma.Journal of cellular and molecular medicine · 2023Article
- Specific Targeting and Labeling of Colonic Polyps inCurrent issues in molecular biology · 2023Article
- Review
- Review
- Role of gut microbiota and bacterial metabolites in mucins of colorectal cancer.Frontiers in cellular and infection microbiology · 2023Review
- Immunohistochemical analysis of Tn antigen expression in colorectal adenocarcinoma and precursor lesions.BMC cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 3 countries.
Funding
Abstract
Development of biomarkers that detect early stage resectable premalignant lesions of colon can provide critical aid in the prevention of colorectal cancer. Recent lines of evidence suggest the utility of mucin expression to predict malignant transformation of colon pre-neoplastic lesions. In this study, we investigated the combined expression of multiple mucins and mucin-associated glycans during the adenoma-carcinoma sequence of colon cancer progression. Further, we evaluated their applicability as markers for differentiating adenomas/adenocarcinomas from hyperplastic polyps. Immunohistochemical analyses performed on colon disease tissue microarrays revealed downregulation of MUC2 and MUC4 expression (p < 0.0001) while MUC1 and MUC5AC expressions were upregulated (p = 0.01) during adenoma-adenocarcinoma progression. Expression of MUC17 was downregulated in inflamed tissues compared to normal tissues, but its increased expression differentiated adenomas (p = 0.0028) and adenocarcinomas (p = 0.025) from inflammation. Glycan epitope-Tn/STn on MUC1 showed higher expression in hyperplastic polyps (p = 0.023), adenomas (p = 0.042) and adenocarcinomas (p = 0.0096) compared to normal tissues. Multivariate regression analyses indicated that a combination of MUC2, MUC5AC, and MUC17 could effectively discriminate adenoma-adenocarcinoma from hyperplastic polyps. Altogether, a combined analysis of altered mucins and mucin-associated glycans is a useful approach to distinguish premalignant/malignant lesions of colon from benign polyps.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.